Revvity, Inc. reported a total revenue of $729.7 million for the second quarter of fiscal year 2026, reflecting a 1% increase from $720.3 million in the same period last year. The growth was driven by a 5% increase in the Diagnostics segment, which generated $371.0 million, while the Life Sciences segment saw a 2% decline to $358.7 million. For the first half of the fiscal year, total revenue reached $1.44 billion, up 4% from $1.39 billion in the prior year. The company’s net income for the quarter was $51.8 million, down from $53.9 million a year earlier, resulting in diluted earnings per share of $0.47, compared to $0.46 in the previous year.
The company experienced a notable increase in gross margins, which rose to 57.1% from 54.5% year-over-year, attributed to tariff refunds and a favorable product mix. However, operating margins decreased slightly from 12.6% to 12.2%, primarily due to restructuring charges and investments in digital initiatives. Selling, general, and administrative expenses increased by 12% to $278.6 million, driven by restructuring costs and digital investments. Research and development expenses decreased by 8% to $49.0 million, reflecting cost containment efforts.
In terms of strategic developments, Revvity completed the acquisition of Advanced Chemistry Development Inc. for $72 million, enhancing its Life Sciences segment. The company also undertook restructuring efforts that affected approximately 5% of its workforce, aimed at streamlining operations. The total headcount as of July 5, 2026, was not disclosed, but the restructuring is expected to yield long-term operational efficiencies.
Revvity's cash and cash equivalents stood at $1.02 billion, with $1.5 billion available under its senior unsecured revolving credit facility. The company repurchased 93,303 shares for $7.8 million during the quarter, with $792.7 million remaining under its stock repurchase program. The company also declared a quarterly dividend of $0.07 per share, consistent with previous quarters. Looking ahead, Revvity anticipates continued revenue growth driven by its Diagnostics segment and ongoing investments in product development, while remaining cautious of potential market volatility and economic conditions that could impact operations.
About REVVITY, INC.
Revvity, Inc. is a global provider of health science solutions, offering products and services in life sciences and diagnostics. Its core activities include developing technologies for research, drug discovery, and clinical diagnostics, serving pharmaceutical, biotech, healthcare, and research markets worldwide. The company focuses on innovation, strategic acquisitions, and operational excellence to deliver workflows, reagents, instruments, and software that advance healthcare and scientific discovery.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov